Brief: Sunesis Pharmaceuticals Announces Clinical Update On Vecabrutinib Program

Viracta Therapeutics

23/06/2020 12:45

June 23 (Reuters) - Sunesis Pharmaceuticals Inc  SNSS.O :
    * SUNESIS PHARMACEUTICALS ANNOUNCES CLINICAL UPDATE ON
VECABRUTINIB PROGRAM
    * SUNESIS - WON'T ADVANCE NON-COVALENT BTK INHIBITOR
VECABRUTINIB
INTO PLANNED PHASE 2 PORTION OF PHASE 1B/2 TRIAL IN ADULTS WITH
RELAPSED/REFRACTORY CLL
    * SUNESIS PHARMACEUTICALS - EXPECT THAT CURRENT CASH
RESOURCES ARE
SUFFICIENT TO FUND COMPANY INTO 2021
    * SUNESIS PHARMA - DECISION TO NOT ADVANCE WAS MADE AFTER
ASSESSING TOTALITY OF DATA INCLUDING 500 MG COHORT, HIGHEST DOSE
STUDIED IN TRIAL
    * SUNESIS PHARMACEUTICALS - RESOURCES AND DEVELOPMENT FOCUS
TO
FIRST-IN-CLASS PDK1 INHIBITOR SNS-510
    * SUNESIS PHARMA - REMAIN ON TRACK TO FILE AN IND BY END OF
2020,EXPECT TO PRESENT ADDITIONAL PRECLINICAL FINDINGS AT
MEDICAL MEETING IN H2 OF YEAR
    * SUNESIS PHARMA - DID NOT SEE A REDUCTION IN TUMOR BURDEN
IN ANY
PATIENTS WITH STABLE DISEASE IN COHORT 7 OF VECABRUTINIB PHASE
1B/2 TRIAL
    * SUNESIS PHARMACEUTICALS -  CONDUCTING IND-ENABLING PROGRAM
FOR
SNS-510 & PLAN TO FILE IND BY END OF 2020
    * SUNESIS PHARMA - INSUFFICIENT EVIDENCE OF ACTIVITY IN
BTK-INHIBITOR RESISTANT B-CELL MALIGNANCIES TO ADVANCE DRUG INTO
PLANNED PHASE 2 PORTION OF TRIAL

Source text for Eikon:  ID:nGNX2tzSQf 
Further company coverage:  SNSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))